|
If you need more information about ACOMPLIA®: |
ACOMPLIA® approved in the European Union June 20, 2006 ACOMPLIA® (rimonabant) approved in the European Union as an adjunct to diet and exercise for the treatment of obese patients (BMI ≥ 30 kg/m2), or overweight patients (BMI > 27 kg/m2) with associated risk factors such as type 2 diabetes or dyslipidemia. Chairman's messageAction of rimonabantDownload / order documents |
Information is intended to journalists and investors